PROVECTUS BIOPHARMACEUTICALS's ticker is PVCT and the CUSIP is 74373P108. A total of 8 filers reported holding PROVECTUS BIOPHARMACEUTICALS in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $2,000 | 0.0% | 29,750 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | 0.0% | 29,750 | 0.0% | 0.00% | – |
| Q1 2021 | $2,000 | 0.0% | 29,750 | +14.4% | 0.00% | -100.0% |
| Q4 2020 | $2,000 | 0.0% | 26,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $2,000 | +100.0% | 26,000 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | -50.0% | 26,000 | -8.8% | 0.00% | -100.0% |
| Q3 2018 | $2,000 | 0.0% | 28,500 | -64.2% | 0.00% | 0.0% |
| Q4 2016 | $2,000 | -75.0% | 79,500 | 0.0% | 0.00% | -66.7% |
| Q3 2016 | $8,000 | -74.2% | 79,500 | -5.9% | 0.00% | -76.9% |
| Q2 2016 | $31,000 | -3.1% | 84,500 | 0.0% | 0.01% | -13.3% |
| Q1 2016 | $32,000 | -13.5% | 84,500 | -10.6% | 0.02% | -11.8% |
| Q4 2015 | $37,000 | -31.5% | 94,500 | 0.0% | 0.02% | -37.0% |
| Q3 2015 | $54,000 | -10.0% | 94,500 | -15.2% | 0.03% | +12.5% |
| Q2 2015 | $60,000 | -22.1% | 111,500 | +18.0% | 0.02% | -22.6% |
| Q1 2015 | $77,000 | +4.1% | 94,500 | +2.2% | 0.03% | +10.7% |
| Q4 2014 | $74,000 | – | 92,500 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,200,000 | $1,265,000 | 0.20% |
| SABBY MANAGEMENT, LLC | 1,982,137 | $1,140,000 | 0.05% |
| Cutter & CO Brokerage, Inc. | 94,500 | $54,000 | 0.03% |
| PRINCETON CAPITAL MANAGEMENT LLC | 25,000 | $14,000 | 0.02% |
| LUPO SECURITIES, LLC | 3,700 | $2,000 | 0.02% |
| B. Riley Wealth Advisors, Inc. | 28,000 | $17,000 | 0.00% |
| WADE G W & INC | 30,000 | $17,000 | 0.00% |
| Cannell & Co. | 90,000 | $52,000 | 0.00% |
| Focused Wealth Management, Inc | 2,955 | $2,000 | 0.00% |
| TRUST DEPARTMENT MB FINANCIAL BANK N A | 10,000 | $6,000 | 0.00% |